ASTCT 2024 Clinical Education Conference October 17–18, 2024 St. Louis, MO

### **TARGET AUDIENCE**

This activity is intended for physicians, fellows, advanced practice providers (APPs), and in-training health care professionals who treat patients with hematopoietic cell transplantation and cellular therapies.

### **PROGRAM OVERVIEW**

The ASTCT Clinical Education Conference (CEC) provides a deeper understanding of the diagnostic evaluations and therapeutic treatments for acute and chronic complications of hematopoietic cell transplantation and cellular therapies. During this two-day event, learners will participate in breakout sessions that will dig deeper into case studies and treatments of either the adult or pediatric patient populations. In addition, the CEC offers a track specially designed for beginners (defined as individuals at about one year into their professional careers).

# **LEARNING OBJECTIVES**

Upon completion of this course, the participants should be able to:

- Describe the latest trends in the stem cell transplantation and cellular therapy fields
- Incorporate new or additional methods of supportive care to reduce patient complications and improve quality of life
- Identify opportunities to improve your current clinical practice

# INSTRUCTIONS FOR PARTICIPATION AND REQUESTING CREDIT

There are no fees for participating and receiving credit for this activity. Successful completion is achieved by reviewing the CE information, completing the activity, and completing the post-test and evaluation form.

# **Credit Fulfillment**

 If you are requesting AMA/ANCC credits or a certificate of participation, your certificate will be available for download

# **ACCREDITED PROVIDERS**

This activity is provided by The France Foundation in collaboration with the American Society for Transplantation and Cellular Therapy (ASTCT).





### **ACCREDITATION STATEMENT**

In support of improving patient care, The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care

# **Physician Credit Designation**

INTERPROFESSIONAL CONTINUING EDUCATION



The France Foundation designates this live activity for a maximum of 13.5 AMA PRA Category 1 Credit(s) $^{TM}$ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

# **Nurses**



The France Foundation designates this activity for 13.5 contact hours.

All other health care professionals completing this accredited activity may receive a statement of participation.

# **DISCLOSURE POLICY**

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and ASTCT require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and ASTCT resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs.

Furthermore, TFF and ASTCT seek to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and ASTCT are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.

Name of Individual	Role in Activity	Name of Commercial Interest(s)	Nature of Relationship(s)	Mechanism(s) implemented to resolve conflict of interest
Alexandra Gomez Arteaga, MD	Planning Committee Member	1. Kite Pharma	1. Non-CE Consulting	The following financial relationship was mitigated by ending in October 2023  Kite Pharma

Г	T		T	
				All final planning decisions concerning content, learning objectives, and evaluation questions were made by the nonconflicted planning committee members
Allie Hunefeld, MA, CCLS	Faculty	No relevant financial relationships	N/A	N/A
Amber Jewison, CPNP-PC	Planning Committee Member	No relevant financial relationships	N/A	N/A
Angela Krach, APRN, AGPCNP	Faculty	No relevant financial relationships	N/A	N/A
Ashley Meyer, CPNP	Faculty	No relevant financial relationships	N/A	N/A
Ashley Rumsey, MSN, APRN, AGCNS- BC, OCN, BMTCN	Planning Committee Member	No relevant financial relationships	N/A	N/A
Ashley Smeaton, MHA	TFF Staff	No relevant financial relationships	N/A	N/A
Bettina Zerante, BS, RN, MS, AGACNP-BC	Planning Committee Co-Chair, Faculty	No relevant financial relationships	N/A	N/A
Charles Porter, MD	Faculty	No relevant financial relationships	N/A	N/A
Chelsea Honstain, MS, FNP-C, BMTCN	Planning Committee Co-Chair, Faculty	No relevant financial relationships	N/A	N/A
Christine Rimkus, RN, MSN, AOCN	Planning Committee Member	AbbVie, Adaptive,     Amgen, EMD     Serono, Incyte	1. Non-CE Speakers Bureau	All final planning decisions concerning content, learning objectives, and evaluation questions were made by the nonconflicted planning committee members
Christina Ferraro, MSN, APRN-CNP, BMTCN	Planning Committee Member	No relevant financial relationships	N/A	N/A
Corey Cutler, MD	Faculty	Astellas, Cellarity,     CSL Behring, Incyte,     InhibRx,	1. Non-CE consulting	Content was reviewed by a non-conflicted faculty to ensure that it is not

		Mallinckrodt, Novartis, Rigel, Sanofi, Syndax  2. 2Seventy Bio, Actinium Pharmaceuticals, Allogene Therapeutics, Bluebird Bio, Cimeio, OrcaBio, Soligenix, Verastem Oncology	2. Stock ownership of publicly traded companies	commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning
Daniel Olson, MD	Faculty	1. Iovance, Obsidian, Novartis  2. Astellas, Bayer, Immunocore, Inhibrx, Iovance, Turnstone	1. Non-CE Consulting 2. Contract Research	The following financial relationship was mitigated by:  Iovance ended in May 2024  Novartis ended in April 2024  Obsidian ended in November 2023  Content was reviewed by a non-conflicted faculty to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning
Dekozlymn (Dee) Anderson, CRNP	Planning Committee Member	No relevant financial relationships	N/A	N/A
Erin Doherty, MD	Faculty	No relevant financial relationships	N/A	N/A
Frederick Huang, MD	Faculty	1. Children's Oncology Group, Clarity Pharmaceuticals, Jubilant Radiopharma	1. Contract Research	Content was reviewed by a non-conflicted faculty to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning
Guru Murthy, MD, MS	Faculty	1. Amgen, Autolus, BMS, BeiGene,	1. Non-CE Consulting	Content was reviewed by a non-conflicted faculty to ensure that it is not

		Gilead/Kite, Pfizer, Syndax  2. Amgen, Rigel, Stemline	2. Non-CE Speakers	commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning
		3. BeiGene, Gilead,	Bureau  3. Contract	· caseg
		Genmab, Genomics SA, K-Group Alpha, Lilly, LOXO, Oryzon, Schrodinger	Research (funding to institution)	
Heather Tarbox, MPH	TFF Staff	No relevant financial relationships	N/A	N/A
Jeffrey Miller, MSN, APRN, FNP-C	Planning Committee Member	No relevant financial relationships	N/A	N/A
Jennifer Blase, MD, PhD	Faculty	No relevant financial relationships	N/A	N/A
Jessica Doiron, DNP, ANP-C	Faculty	No relevant financial relationships	N/A	N/A
Jessica Fugate, PA-C	Planning Committee Member, Faculty	No relevant financial relationships	N/A	N/A
Joanne Wilson, APRN, DNP	Faculty	No relevant financial relationships	N/A	N/A
John DiPersio, MD, PhD	Faculty	1. RiverVest Ventures, SPARC, Vertex	1. Non-CE Consulting	The following financial relationship was mitigated by:
		2. Bioline Rx, Macrogenics, Neoimmune Tech, WUGEN	2. Contract Research	<ul> <li>RiverVest Ventures ended in September 2024</li> </ul>
		3. hC Bioscience, Inc., Magenta Therapeutics, RiverVest Ventures	3. Advisory Board Member	Content was reviewed by a non-conflicted faculty to ensure that it is not commercially biased, is fair-balanced, and is based on scientific
		4. Magenta Therapeutics, WUGEN	4. Stock options in a publicly traded company; stock options in a company without a commercial	evidence and/or clinical reasoning

			product in	
Johnnie Orozco, MD, PhD	Planning Committee Member	1. Actinium Pharmaceuticals, Inc.	1. Contract Research	The following financial relationship was mitigated by ending in October 2023  Actinium Pharmaceuticals, Inc.  All final planning decisions concerning content, learning objectives, and evaluation questions were made by the nonconflicted planning committee members
Jordan Leal, MSN, AGNP-C, BMTCN	Planning Committee Member	No relevant financial relationships	N/A	N/A
Julie Klinger, PA-C	Planning Committee Member, Faculty	No relevant financial relationships	N/A	N/A
Kate Sortun, ARNP	Planning Committee Member	No relevant financial relationships	N/A	N/A
Kayleigh Schwartz	Faculty	No relevant financial relationships	N/A	N/A
Kelly Brassil, PhD, RN, FAAN	Faculty	Daiichi Sankyo,     Gilead, GSK, Sanofi      Quest Diagnostics	<ol> <li>Contract         Research</li> <li>Stock options         with a publicly         traded company</li> </ol>	Content was reviewed by a non-conflicted faculty to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning
Kelly Terrell, MBA, BSN, RN, BMTCN	Planning Committee Member	No relevant financial relationships	N/A	N/A
Keriann Kordas, MSN	Planning Committee Member, Faculty	No relevant financial relationships	N/A	N/A
Lindsay Adkins, NP	Planning Committee	No relevant financial relationships	N/A	N/A

	Member,			
	Faculty			
Liz Stockton	ASTCT Staff	No relevant financial relationships	N/A	N/A
Liza Rodriguez, ARNP	Planning Committee Co-Chair	No relevant financial relationships	N/A	N/A
Marilyn Schallom, PhD, MSN(R), APRN- BC, CCNS, CCRN, FCCM	Faculty	No relevant financial relationships	N/A	N/A
Meaghan Ryan, MSN, FNP-BC	Planning Committee Member, Faculty	No relevant financial relationships	N/A	N/A
Michelle Skinner, RN, MSN, CPNP-AC	Planning Committee Member, Faculty	No relevant financial relationships	N/A	N/A
Misty Evans, DNP, APRN, CPNP-AC	Planning Committee Member, Faculty	1. Jazz Pharmaceuticals	1. Non-CE Consulting	All final planning decisions concerning content, learning objectives, and evaluation questions were made by the nonconflicted planning committee members
Nickie Mizell	ASTCT Staff	No relevant financial relationships	N/A	N/A
Nilesh Kalariya, PhD, AGPCNP-BC, AOCNP	Faculty	No relevant financial relationships	N/A	N/A
Omar Aljitawi, MBBS	Faculty	No relevant financial relationships	N/A	N/A
Pepita Jean, APRN	Planning Committee Member, Faculty	No relevant financial relationships	N/A	N/A
Phuong Vo, MD	Faculty	No relevant financial relationships	N/A	N/A
Ravi Pingali, MD	Faculty	No relevant financial relationships	N/A	N/A
Ryan Day, MD, PhD	Faculty	No relevant financial relationships	N/A	N/A
Sagun Goyal, MD, MSc	Faculty	No relevant financial relationships	N/A	N/A

Shalini Shenoy, MD	Faculty	1. COG PEP CTN, BMT CTN  2. Bluebird Bio, BioLine, Medexus	1. Contract Research  2. Honoraria for one-time advisory board	Content was reviewed by a non-conflicted faculty to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical
		3. BEAM Therapeutics	3. DSMB	reasoning
		4. California Institute of Regenerative Medicine	4. Scientific Review Board	
Stephanie Bauer, RN, MSN, FNP-BC	Planning Committee Member	No relevant financial relationships	N/A	N/A
Susan Prockop, MD	Faculty	1. New York Cord Bank	1. Non-CE Consulting (DSMB Memberships)	The following financial relationship was mitigated by ending in April 2024  AlloVIR
		2. AlloVIR, Atara, Jasper	2. Contract Research	Content was reviewed by a non-conflicted faculty to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning
Ted Bruno, MD	TFF Content Reviewer	No relevant financial relationships	N/A	N/A
Tyler Robertson, MA, CCLS	Faculty	No relevant financial relationships	N/A	N/A
Zachary Crees, MD	Faculty	1. BioLineRx	1. Non-CE Consulting, Scientific Advisory Board	Content was reviewed by a non-conflicted faculty to ensure that it is not commercially biased, is fair-balanced, and is based on scientific evidence and/or clinical reasoning
Zandra Rivera, NP	Planning Committee Co-Chair	No relevant financial relationships	N/A	N/A

# **Disclosure of Unlabeled Use:**

TFF and ASTCT require faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that are outside of US Food and Drug Administration approved labeling.

This information is intended solely for continuing medical education and is not intended to promote offlabel use of these medications. TFF and ASTCT do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

### COMMERCIAL SUPPORT ACKNOWLEDGMENT

This activity is currently not supported by any independent medical educational grants.

#### Disclaimer

TFF and ASTCT present this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, ASTCT, and the commercial supporter(s) assume no liability for the information herein.

#### CONTACT INFORMATION

If you have questions about this CME/CE activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.